Search

Brian E Vash

from Woburn, MA
Age ~51
Get Report
Also known as:
Brian Edward Vash
Related to:
Trinity N Ristau, 50Claire Anne Lewis-Martin, 76
Connected to:
Charles J Vash, 91Peter D Vash, 78Olesya N Vashchishin, 38Darla L Vasher, 61Bina P Vashi, 62Mehulkumar R Vashi, 55Anirudh Vashishth, 35Aparna Vashisht, 40Pradeep K Vashishtha, 54Sunil D Vashisht, 55

Brian Vash Phones & Addresses

  • Woburn, MA
  • 157 6Th St, Cambridge, MA 02142
  • Medford, MA
  • Newton, MA
  • 4222 Arbor Cir, Shrewsbury, MA 01545 (508) 845-8961
  • Fishkill, NY
  • Arlington, TX
  • Dallas, TX

Publications

Us Patents

Universal Fibronectin Type Iii Bottom-Side Binding Domain Libraries

View page
US Patent:
20120208704, Aug 16, 2012
Filed:
Oct 27, 2010
Appl. No.:
13/504824
Inventors:
Andreas Loew - Somerville MA, US
Brian Edward Vash - Cambridge MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
C40B 40/10
C40B 40/02
C40B 30/04
C40B 10/00
US Classification:
506 1, 506 18, 506 14, 506 9
Abstract:
The invention pertains to a natural-variant combinatorial library of fibronectin Type 3 domain (Fn3) polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity. The library polypeptides include (a) regions A, AB, B, C, CD, D, E, EF, F, and G having wildtype amino acid sequences of a selected native fibronectin Type 3 polypeptide or polypeptides, and (b) loop regions AB, CD, and EF having selected lengths (Bottom Loops). The Fn3 may also have loop regions BC, DE, and FG having wildtype amino acid sequences, having selected lengths, or mutagenized amino acid sequences (Top Loops).

Dimerization Switches And Uses Thereof

View page
US Patent:
20220378833, Dec 1, 2022
Filed:
Jul 22, 2022
Appl. No.:
17/814287
Inventors:
- Basel, CH
Brian Edward Vash - Cambridge MA, US
International Classification:
A61K 35/17
C12N 9/12
C12N 9/90
A61K 48/00
C12N 15/62
Abstract:
The present invention provides gene editing systems comprising gene editing dimerization switches comprising a first and second gene editing switch domain that allow for the regulation of a gene editing function by the introduction, e.g., administration, of a gene editing dimerization molecule having the ability to bring together a first gene editing switch domain and a second gene editing switch domain. A regulated gene editing function provides, e.g., less off-target side effects, and increases the therapeutic window.The present invention also provides improved FKBP/FRB-based dimerization switches wherein the FRB switch domain or the FKBP switch domain, or both the FRB and FKBP switch domains, comprise one or more mutations that optimize performance, e.g., that alter, e.g., enhance the formation of a complex between the first switch domain, the second switch domain, and the dimerization molecule, rapamycin, or a rapalog, e.g., RAD001.

Multispecific And Multifunctional Molecules And Uses Thereof

View page
US Patent:
20220288200, Sep 15, 2022
Filed:
Jan 26, 2022
Appl. No.:
17/584892
Inventors:
- Cambridge MA, US
Brian Edward Vash - Cambridge MA, US
International Classification:
A61K 39/395
C07K 16/30
C07K 16/28
C07K 16/40
C07K 16/32
C07K 14/55
C07K 14/71
C07K 14/705
C07K 14/47
A61K 39/00
A61K 38/17
Abstract:
Multispecific molecules that include i) a tumor-targeting moiety; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Csf1R/Ccr2 Multispecific Antibodies

View page
US Patent:
20220242957, Aug 4, 2022
Filed:
Sep 27, 2019
Appl. No.:
17/280766
Inventors:
- Cambridge MA, US
Brian Edward VASH - Cambridge MA, US
Stephanie J. MAIOCCO - Cambridge MA, US
Peter MAREK - Cambridge MA, US
International Classification:
C07K 16/28
C07K 16/46
A61P 35/00
Abstract:
Molecules, e.g., multispecific molecules, targeting CSF1R or CCR2 and methods of using the same, are disclosed.

Anti-Tcr Antibody Molecules And Uses Thereof

View page
US Patent:
20230127740, Apr 27, 2023
Filed:
Aug 18, 2022
Appl. No.:
17/820800
Inventors:
- Cambridge MA, US
Brian Edward Vash - Cambridge MA, US
Jonathan Hsu - Waltham MA, US
Dilini Charmain Gunasekera - Cambridge MA, US
Sangeetha Sagar Palakurthi - East Walpole MA, US
Andreas Loew - Boston MA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 35/17
C12N 5/078
Abstract:
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Anti-Tcr Antibody Molecules And Uses Thereof

View page
US Patent:
20230031734, Feb 2, 2023
Filed:
Aug 18, 2022
Appl. No.:
17/820818
Inventors:
- Cambridge MA, US
Brian Edward Vash - Cambridge MA, US
Jonathan Hsu - Waltham MA, US
Dilini Charmain Gunasekera - Cambridge MA, US
Sangeetha Sagar Palakurthi - East Walpole MA, US
Andreas Loew - Boston MA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 35/17
C12N 5/078
Abstract:
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Anti-Tcr Antibody Molecules And Uses Thereof

View page
US Patent:
20230034161, Feb 2, 2023
Filed:
Aug 18, 2022
Appl. No.:
17/820806
Inventors:
- Cambridge MA, US
Brian Edward Vash - Cambridge MA, US
Jonathan Hsu - Waltham MA, US
Dilini Charmain Gunasekera - Cambridge MA, US
Sangeetha Sagar Palakurthi - East Walpole MA, US
Andreas Loew - Boston MA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 35/17
C12N 5/078
Abstract:
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Anti-Tcr Antibody Molecules And Uses Thereof

View page
US Patent:
20230025484, Jan 26, 2023
Filed:
Aug 18, 2022
Appl. No.:
17/820634
Inventors:
- Cambridge MA, US
Brian Edward Vash - Cambridge MA, US
Jonathan Hsu - Waltham MA, US
Dilini Charmain Gunasekera - Cambridge MA, US
Sangeetha Sagar Palakurthi - East Walpole MA, US
Andreas Loew - Boston MA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 35/17
C12N 5/078
Abstract:
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Control profile
Brian E Vash from Woburn, MA, age ~51 Get Report